Fact-checked by Grok 2 weeks ago

ACVR1

ACVR1, also known as activin A receptor type 1 or ALK2, is a gene located on chromosome 2q24.1 that encodes a 509-amino-acid serine/threonine kinase receptor belonging to the transforming growth factor beta (TGF-β) superfamily. The encoded protein serves as a type I receptor primarily for bone morphogenetic proteins (BMPs), forming heteromeric complexes with type II receptors to transduce signals that regulate key developmental processes, including osteogenesis, chondrogenesis, cell differentiation, and tissue homeostasis in bone, muscle, heart, cartilage, nervous system, and reproductive organs. ACVR1 is ubiquitously expressed across human tissues, with notably high levels in the placenta, skeletal muscle, heart, thyroid, and gall bladder. In normal , ACVR1 mediates signaling by phosphorylating receptor-regulated SMAD proteins (SMAD1/5/8) upon binding, which then complex with SMAD4 to enter the and modulate target ; it also participates in non-canonical pathways such as p38 MAPK and PI3K/AKT/mTOR to influence , survival, and migration. The receptor's includes an extracellular for interaction, a single transmembrane , and an intracellular essential for signal propagation, with regulatory elements like the glycine-serine (GS) domain controlling activation. Mutations in ACVR1 are most notably associated with (FOP), a rare autosomal dominant disorder characterized by progressive heterotopic ossification of soft tissues, leading to skeletal deformities and loss of mobility; the recurrent R206H in the GS domain, present in nearly all classic FOP cases, causes ligand-independent activation and aberrant responsiveness to activin A, resulting in dysregulated BMP signaling and ectopic bone formation. Other ACVR1 variants, such as G328R, G356D, and R375P, contribute to atypical FOP phenotypes with variable severity, while additional mutations like G356D are linked to congenital heart defects, including atrioventricular septal defects. Beyond FOP, somatic ACVR1 occur in approximately 20-30% of diffuse intrinsic pontine gliomas (DIPG), a pediatric cancer, where they drive oncogenic signaling; dysregulation of ACVR1 also plays roles in various cancers, such as ovarian, endometrial, and cancers, often promoting tumor progression through altered BMP pathway activity.

Genetics

Genomic location

The ACVR1 gene is located on the long arm of human chromosome 2 at the cytogenetic band 2q24.1. In the GRCh38.p14 reference assembly, it spans from nucleotide position 157,736,446 to 157,876,330 on the reverse (complement) strand, encompassing approximately 140 kb of genomic sequence. The gene's orientation on the reverse strand facilitates its transcription in the opposite direction relative to the chromosomal coordinate increase. In comparison, the mouse ortholog Acvr1 is situated on chromosome 2 at positions 58,336,450 to 58,456,840 (also on the complement strand) in the GRCm39 assembly, covering about 120 kb within the 58.3–58.5 Mb region. Evolutionary conservation of ACVR1 is high across mammals, with the and proteins sharing 99.8% identity, reflecting its essential role in conserved signaling pathways. The ACVR1 gene was first cloned in as part of efforts to identify type I receptors in the transforming growth factor-beta (TGF-β) superfamily, with subsequent mapping to 2q23-q24 confirmed by in 1998.

Gene structure

The ACVR1 gene consists of 11 exons spanning approximately 140 kb of genomic DNA on chromosome 2q24.1. Exon 1 includes the translation start codon (ATG) along with 5' untranslated regions (UTRs), while the subsequent exons encode the remainder of the coding sequence, interrupted by 10 introns of varying lengths that account for the gene's overall size. The canonical transcript, ENST00000263640.7, utilizes these 11 exons with standard GT-AG consensus splice sites at intron-exon boundaries, producing a 3,047 bp mRNA that encodes a 509-amino-acid protein isoform. Alternative splicing generates at least 52 transcripts for ACVR1, though most variants differ primarily in UTR composition rather than regions, with ENST00000263640.7 designated as the principal isoform due to its high and expression levels. sizes contribute significantly to the genomic footprint; for instance, studies in bovine models have identified structural features such as indels within 1 (e.g., g.2715_2731del, a 17-bp deletion) and 2 (e.g., g.33008_33024del, another 17-bp deletion, rs380635814), highlighting the intronic variability across . Regulatory elements upstream of the include a 2.9 promoter with a transcription start site (TSS) located 237-244 bp upstream of the ATG codon. This promoter features a GC-rich minimal core (72 bp) lacking a and driven by Sp1 binding for basal transcription, while an upstream region acts as an enhancer-like element responsive to bone morphogenetic protein 2 (). Transcription factors such as Egr-1, Egr-2, ZBTB7A/LRF, and Hey1 bind within this promoter, exhibiting cell-type-specific regulation that has been characterized in studies of (). In non-human models like Chinese beef cattle, ACVR1 variations—including the aforementioned intronic indels and exonic single nucleotide polymorphisms (SNPs) such as g.41793C>T (exon 4, rs458497709)—are associated with traits, including increased chest girth and bone circumference, suggesting functional roles for these structural elements in phenotypic variation.

Protein

Primary structure

The ACVR1 protein consists of 509 and has a calculated molecular weight of approximately 57 . It is synthesized as a precursor with an N-terminal comprising the first 20 (residues 1–20), which facilitates translocation across the membrane during . The primary amino acid sequence of ACVR1 features characteristic motifs typical of serine/ receptors, including a conserved serine/ domain in the intracellular region that enables autophosphorylation and signal propagation. Additionally, the sequence contains potential N-linked sites in the extracellular domain, where residues serve as attachment points for chains, contributing to , stability, and trafficking. A key post-translational modification is N-linked , which occurs primarily in the extracellular portion and influences the protein's maturation in the secretory pathway. ACVR1 exhibits strong sequence conservation across mammals, with greater than 85% identity in the coding regions between and orthologs, including the , underscoring its evolutionary importance in conserved signaling pathways. This high extends to functional motifs, ensuring similar biochemical properties in different species. ACVR1 is a single-pass type I , with the cleaved to yield the mature form.

Domain organization

The ACVR1 protein, a serine/threonine kinase receptor, exhibits a modular domain architecture typical of type I transforming growth factor-β (TGF-β) superfamily receptors, spanning 509 in its precursor form and yielding a mature protein of 489 amino acids after cleavage of the N-terminal (residues 1-20). The extracellular domain (residues 21-124 of the precursor) is cysteine-rich, facilitating ligand binding and promoting receptor dimerization through disulfide bond formation. This region contains conserved residues that stabilize the for interaction with bone morphogenetic proteins (BMPs) and activins. Adjacent to the extracellular domain is the transmembrane domain (residues 125-147), which consists of an alpha-helical span that anchors the protein in the plasma membrane and mediates signal transduction from extracellular to intracellular compartments. The intracellular portion begins with the GS domain (residues 148-179), a glycine- and serine-rich regulatory segment that serves as a phosphorylation site for activation by type II receptors. The C-terminal kinase domain (residues 180-503) harbors the catalytic activity, featuring an activation loop essential for substrate phosphorylation and downstream signaling initiation. Structural studies have elucidated key features of these domains. The kinase domain has been crystallized in complex with inhibitors, as seen in PDB entry 9D8F, revealing inhibitor binding in the ATP pocket via van der Waals interactions and hydrogen bonds that stabilize the inactive conformation. Additionally, cryo-electron microscopy structures demonstrate a heterodimeric between the ACVR1 domain and the type II receptor BMPR2, mediated by interactions between their C-terminal lobes, which positions the GS domain for trans-phosphorylation.

Ligand binding and signaling

Receptor complex formation

ACVR1, also known as ALK2, functions as a type I receptor in the bone morphogenetic protein (BMP) signaling pathway, assembling into heterotetrameric complexes consisting of two type I receptors and two type II receptors to transduce extracellular signals. These complexes typically include ACVR1 alongside another type I receptor such as BMPR1A (ALK3) or BMPR1B (ALK6), paired with type II receptors like BMPR2, ACVR2A, or ACVR2B. The symmetric heterotetramer forms around a dimeric , with the extracellular domains of the receptors interacting to stabilize the assembly, enabling subsequent intracellular activation. Ligand binding initiates complex formation, with BMPs such as BMP6 and BMP7 exhibiting primary affinity for these receptor assemblies, while activins can also engage ACVR1, often forming non-signaling complexes. The extracellular domain of ACVR1 plays a crucial role in facilitating dimerization by interacting with the ligand's binding sites, which have comparable affinities for type I and type II receptors in BMPs, promoting the recruitment of all four receptor subunits. Ligands bind with low affinity to type I receptors like ACVR1 in isolation, necessitating the presence of type II receptors for high-affinity, stable interactions that drive tetramerization. Receptor associations exhibit both constitutive and ligand-induced characteristics, with type I and type II receptors forming transient homodimers or heterodimers in the absence of , maintaining a basal state of low activity. Ligand binding enhances oligomerization, stabilizing the heterotetrameric and shifting it toward active signaling conformations through extracellular domain rearrangements and intracellular kinase domain interactions. Accessory proteins such as FKBP1A (also known as FKBP12) bind to the glycine-serine (GS) domain of ACVR1, regulating complex stability by inhibiting premature kinase activation and preventing leaky signaling until ligand-induced conformational changes release the inhibitor.

Downstream signaling

Upon ligand-induced formation of the receptor complex, the associated type II receptor (such as BMPR2 or ACVR2A/B) transphosphorylates the glycine-serine (GS) domain of ACVR1 at multiple serine residues, which activates the kinase domain of ACVR1 by relieving autoinhibition and dissociating the inhibitory protein FKBP12. This phosphorylation event is essential for propagating the signal intracellularly, as it enables ACVR1 to adopt an active conformation capable of substrate recognition. The activated ACVR1 kinase subsequently phosphorylates the receptor-regulated SMADs (R-SMADs)—specifically SMAD1, SMAD5, and SMAD8—at the C-terminal SSXS motif, leading to their activation. These phosphorylated R-SMADs oligomerize with the common partner SMAD4 to form heterocomplexes that translocate from the cytoplasm to the nucleus, where they interact with DNA and co-factors to induce or repress transcription of target genes such as ID1 and MSX2, which are involved in cell differentiation and proliferation. Negative regulation of ACVR1 signaling occurs primarily through inhibitory SMADs, SMAD6 and SMAD7; SMAD6 competes with R-SMADs for to ACVR1 or promotes their ubiquitination via Smurf1, while SMAD7 directly inhibits type I receptor activity and recruits E3 ligases for receptor degradation. Furthermore, cross-talk with other TGF-β superfamily branches modulates pathway output, as TGF-β-activated SMAD2/3 complexes can antagonize SMAD1/5/8-driven transcription, influencing cellular responses like osteogenesis and .

Physiological functions

Role in development

ACVR1 plays a critical role in early embryonic patterning through its mediation of signaling. In embryos, global ablation of Acvr1 arrests development at stages, resulting in failure of the to undergo proper and formation. This receptor also contributes to dorsoventral axis formation, as its deletion disrupts development, leading to axis defects, consistent with 's morphogenic role in establishing ventral fates. Furthermore, ACVR1 is essential for left-right asymmetry, where signaling through this receptor in chimeric embryos ensures proper nodal expression and asymmetric organ positioning. In skeletal development, ACVR1 regulates , the process by which is gradually replaced by during embryogenesis. It controls the growth and differentiation of chondrocytes and osteoblasts, ensuring coordinated formation in the axial and . Dysregulation of ACVR1, as seen in conditional knockouts, impairs this transition and leads to skeletal malformations, highlighting its necessity for proper timing and progression. Additionally, ACVR1 is involved in formation, particularly in development, where it influences interzone specification and to prevent fusion and enable articulation. ACVR1-mediated BMP signaling is vital for cardiac , specifically in outflow tract septation and valve formation. In heart field, Acvr1 deletion causes misalignment of the outflow tract and defective septation, resulting in common arterial trunk anomalies due to impaired addition of cardiomyocytes and cushion maturation. For semilunar valves, ACVR1 promotes endocardial in the outflow tract, and its deficiency leads to formation through reduced cushion growth and remodeling. In the , ACVR1 supports cell and dorsal patterning via pathway activation. Conditional ablation in cells using Wnt1-Cre reveals that ACVR1 is required for their proliferation and growth, essential for craniofacial structure formation. It also contributes to dorsal patterning by facilitating gradients that specify dorsal identities and inhibit ventral fates during .

Tissue-specific roles

In bone and cartilage, ACVR1 functions as a key type I receptor for bone morphogenetic proteins (BMPs), maintaining by balancing differentiation and activity. Conditional of Acvr1 in leads to increased mass through enhanced osteogenesis and reduced , demonstrating its role in regulating adult skeletal remodeling. In cartilage, ACVR1 supports proliferation and production, ensuring tissue integrity during mechanical stress; its ablation impairs these processes, leading to reduced cartilage maintenance. For repair and remodeling, BMP signaling through ACVR1 activates periosteal progenitor cells during fracture healing, promoting and callus formation to restore structure. In the , ACVR1 mediates (AMH) signaling in the ovaries to regulate , inhibiting the activation of primordial follicles and preserving the in adulthood. Polymorphisms in ACVR1, such as rs1220134, are associated with altered AMH levels and follicle numbers in conditions like , highlighting its influence on ovarian function. In the testes, ACVR1 is expressed in Sertoli cells and spermatogonia, where it supports by facilitating and through and activin pathways. In the heart, ACVR1 contributes to cardiomyocyte maintenance by transducing signals that regulate contractility and calcium handling; disruption of this pathway, such as through elevated activin A binding, impairs diastolic function and promotes in adult cardiomyocytes. During response, ACVR1-mediated BMP7 signaling enhances cardiomyocyte and post-myocardial , aiding repair via activation of SMAD5, ERK, and AKT pathways in adult mice. In the adult , ACVR1 supports by modulating signaling in response to , where its inhibition in neural precursor cells promotes survival and limits demyelination in conditions like .

Pathophysiology

Mutations

The , encoding the activin A receptor type I (also known as ALK2), harbors several gain-of-function that lead to aberrant activation of () signaling. The most prevalent in humans is R206H, a heterozygous missense variant in the glycine-serine (GS) domain, accounting for over 95% of classic (FOP) cases. This substitution reduces the receptor's binding affinity to the inhibitory protein FKBP1A (also known as FKBP12), thereby preventing FKBP1A-mediated suppression of basal activity and promoting ligand-independent signaling. Less common gain-of-function variants in FOP include substitutions at 328 (G328V, G328R, G328W, and G328E) within the domain and R258S in the ATP-binding region. These , identified in a small subset of atypical FOP patients, similarly confer constitutive activity independent of ligand binding, though they exhibit variable sensitivity to BMP ligands compared to R206H. Activating ACVR1 mutations also occur somatically in diffuse intrinsic pontine (DIPG), a pediatric tumor, where approximately 20-25% of cases harbor variants such as R206H or G328 alterations (including G328V, G328R, G328E, and G328W). These mutations drive ligand-independent pathway activation, often co-occurring with K27M alterations to promote gliomagenesis. Loss-of-function variants in ACVR1 are rare in humans but have been linked to congenital heart defects. Neutral variants have not been robustly linked to any diseases. In animal models, such variants are associated with altered growth traits, including increased bone mass in Acvr1-deficient mouse osteoblasts due to upregulated Wnt signaling and enhanced body weight or carcass traits in ACVR1 variant .

Associated diseases

Fibrodysplasia ossificans progressiva () is a rare primarily caused by activating mutations in ACVR1, leading to progressive heterotopic of soft tissues such as muscles, tendons, and ligaments. Clinical features include congenital malformations, most notably bilateral hallux valgus (short, broad, and often clinodactylous big toes) in over 97% of cases, alongside episodic flare-ups that result in painful swellings and subsequent bone formation, severely restricting mobility. The condition has a worldwide prevalence of approximately 1 in 1 to 2 million individuals, with no ethnic or geographic predisposition, and is often triggered by trauma, , or even minor procedures like vaccinations. relies on characteristic clinical findings combined with confirming heterozygous pathogenic variants in ACVR1, such as the common R206H . Diffuse intrinsic pontine glioma (DIPG), a highly aggressive pediatric tumor, is associated with ACVR1 mutations in about 25% of cases, frequently co-occurring with H3.1 K27M mutations. These mutations hyperactivate signaling, promoting tumor cell proliferation, survival, and a mesenchymal that drives genesis and reduces overall survival (median around 11 months). Affected children typically present with cranial nerve deficits, , and long-tract signs, with the location making surgical resection impossible and contributing to poor prognosis. ACVR1 dysregulation has also been implicated in congenital cardiac malformations, including atrioventricular septal defects and , where loss-of-function mutations such as H286D and G356D impair endocardial cushion development during embryogenesis. In the , ACVR1 variants are linked to disorders such as (PCOS) and , potentially contributing to premature ovarian insufficiency through disrupted signaling and . Additionally, ACVR1 gene amplifications or altered expression have been observed in various cancers, including (promoting invasion) and (enhancing proliferation via pathway activation), though these associations are less prevalent (e.g., ~3% in ) and highlight a context-dependent oncogenic role.

References

  1. [1]
    90 - Gene ResultACVR1 activin A receptor type 1 [ (human)] - NCBI
    Sep 27, 2025 · Results showed that ACVR1 was a direct target of miR-384 and was involved in the inhibitory effects of miR-384 on breast cancer progression.
  2. [2]
    Entry - *102576 - ACTIVIN A RECEPTOR, TYPE I; ACVR1 - OMIM
    A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date.
  3. [3]
    ACVR1 Function in Health and Disease - PMC - NIH
    It is involved in a wide variety of biological processes, including bone, heart, cartilage, nervous, and reproductive system development and regulation.
  4. [4]
    Acvr1 activin A receptor, type 1 [ (house mouse)] - NCBI
    Sep 24, 2025 · Enables activin binding activity; transforming growth factor beta binding activity; and transmembrane receptor protein serine/threonine kinase activity.
  5. [5]
    Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2 ...
    The human and mouse ALK2/ACVR1 proteins show 99.8% homology in overall amino acid sequences, though the signal peptides are slightly less homologous (85.0%) ...
  6. [6]
    Identification of human activin and TGF beta type I receptors that ...
    Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors ... Cell. 1993 Nov 19;75(4):671-80.
  7. [7]
    Entry - *102576 - ACTIVIN A RECEPTOR, TYPE I; ACVR1 - OMIM
    (1998) mapped the ACVR1 gene to chromosome 2. By fluorescence in situ ... Chromosomal localization of three human genes encoding members of the TGF ...
  8. [8]
    ACVR1 (activin A receptor, type I)
    Apr 1, 2013 · The protein contains 509 amino acids residues and comprises a single transmembrane and three conserved domains, including: - Activin-recp domain ...
  9. [9]
  10. [10]
    Transcript: ENST00000263640.7 (ACVR1-201) - Summary - Ensembl
    Chromosome 2: 157,736,444-157,875,111 reverse strand. ... This transcript has 11 exons, is annotated with 193 domains and features and maps to 563 oligo probes.
  11. [11]
    Gene: ACVR1 (ENSG00000115170) - Summary - Ensembl
    Chromosome 2: 157,736,249-157,876,347 reverse strand. GRCh38:CM000664.2. About this gene ... This gene maps to 158,592,761-158,732,859 in GRCh37 coordinates. View ...
  12. [12]
    The ACVR1 gene is significantly associated with growth traits in Chinese beef cattle
    ### Summary of ACVR1 Gene Variations in Cattle Associated with Growth Traits
  13. [13]
    Identification and characterization of regulatory elements in the ...
    The ACVR1 gene encodes a type I receptor for bone morphogenetic proteins (BMPs). Mutations in the ACVR1 gene are associated with Fibrodysplasia Ossificans ...
  14. [14]
    Identification and characterization of regulatory elements ... - PubMed
    Sep 18, 2013 · Our results showed that several transcription factors such as Egr-1, Egr-2, ZBTB7A/LRF, and Hey1, regulate the ACVR1 promoter by binding to the -762/-308 ...Missing: exons introns
  15. [15]
    ACVR1 - Activin receptor type-1 - Homo sapiens (Human) - UniProt
    Bone morphogenetic protein (BMP) type I receptor that is involved in a wide variety of biological processes, including bone, heart, cartilage, nervous, ...
  16. [16]
    Accumulated Knowledge of Activin Receptor-Like Kinase 2 (ALK2 ...
    Recently, the gene responsible for PFH was mapped to human chromosome 2q31.1, which contains the ACVR1 gene. It has been suggested that ALK2/ACVR1 is involved ...Missing: history | Show results with:history
  17. [17]
    Mutational analysis of the ACVR1 gene in Italian patients affected ...
    Oct 1, 2008 · The cytoplasmic domain of ACVR1 displays substantial sequence similarity (66% identical residues along the amino-acid stretch 170–500) with the ...
  18. [18]
  19. [19]
    Structural basis for ALK2/BMPR2 receptor complex signaling ...
    Aug 16, 2021 · We show that the kinase domain of the type I receptor ALK2 and type II receptor BMPR2 form a heterodimeric complex via their C-terminal lobes.
  20. [20]
    Heterodimer-heterotetramer formation mediates enhanced sensor ...
    Sep 30, 2021 · Signaling by heterodimers occurs through a hetero-tetrameric receptor complex comprising of two distinct type one BMP receptors and two type II ...
  21. [21]
    CryoEM structure of ALK2:BMP6 reveals distinct mechanism ... - PNAS
    Such heterotetramers form with unglycosylated BMP6 would fail to signal, as only glycosylated BMP6 can activate ALK2. Supporting this, artificial formation of ...
  22. [22]
    Activin A forms a non-signaling complex with ACVR1 and type II ...
    Jun 9, 2020 · Activin A functions in BMP signaling in two ways: it either engages ACVR1B to activate Smad2/3 signaling or binds ACVR1 to form a non-signaling complex (NSC).
  23. [23]
  24. [24]
    The fibrodysplasia ossificans progressiva R206H ACVR1 mutation ...
    Oct 12, 2009 · BMPs, members of the TGF-β superfamily, were identified initially as a family of proteins that could induce ectopic bone formation through an ...
  25. [25]
    The roles and regulatory mechanisms of TGF-β and BMP signaling ...
    Jan 24, 2024 · As such, some target genes have been identified for TGF-β and BMP signaling, including Id-1, Gremlin, noggin, follistatin (FS), Smad6, and BambI ...
  26. [26]
    Molecular characterization of known and novel ACVR1 variants in ...
    Jun 26, 2019 · To date, there have been no reports suggesting that upregulation of Msx2 or ID1 through ACVR1 signaling is independent of upstream SMAD ...
  27. [27]
    TGF-β signaling in health and disease - ScienceDirect
    Sep 14, 2023 · SMAD6 and SMAD7 are inhibitory SMADs that antagonize SMAD4 and the type I receptors, respectively. TGF-β, BMP, interferon-γ (IFN-γ), and ...
  28. [28]
    The Interactivity between TGFβ and BMP Signaling in ... - MDPI
    The Transforming Growth Factor beta and Bone Morphogenic Protein (BMP) pathways intersect at multiple signaling hubs and cooperatively or counteractively ...
  29. [29]
    Common mutations in ALK2/ACVR1, a multi-faceted receptor, have ...
    Activin receptor-like kinase-2 (ALK2), the product of ACVR1, is a member of the type I bone morphogenetic protein (BMP) receptors.<|control11|><|separator|>
  30. [30]
    BMP Signaling: Lighting up the Way for Embryonic Dorsoventral ...
    Furthermore, either Bmpr1a (ALK3) or Acvr1 (ALK6) deletion alone causes significant disruption of primitive streak formation, which may cause subsequent axis ...
  31. [31]
    BMP signaling through ACVRI is required for left-right patterning in ...
    This study tests the role of the BMP type I receptor ACVRI in establishing left-right asymmetry in chimeric mouse embryos.
  32. [32]
    ACVR1 gene: MedlinePlus Genetics
    Jul 15, 2022 · It helps to control the growth and development of the bones and muscles, including the gradual replacement of cartilage by bone (ossification).
  33. [33]
    Dysregulated BMP signaling through ACVR1 impairs digit joint ... - NIH
    Nov 17, 2020 · The Acvr1 R206H mutation leads to delayed and disrupted joint specification and cleavage in the digits and alters the development of cartilage and endochondral ...
  34. [34]
    AcvR1-mediated BMP signaling in second heart field is required for ...
    By removing Acvr1 using the driver Mef2c[AHF]-Cre, we show that AcvR1 plays an essential role in arterial pole morphogenesis, identifying defects in outflow ...
  35. [35]
    Deficient signaling via Alk2 (Acvr1) leads to bicuspid aortic valve ...
    Apr 19, 2012 · These defects are largely due to a failure of normal development of the embryonic aortic valve leaflet precursor cushions in the outflow tract ...
  36. [36]
    The BMP Pathway and Its Inhibitors in the Skeleton
    Aug 29, 2018 · In this review, we wish to provide a comprehensive overview of the BMP pathway and its inhibitors in bone development, homeostasis, and disease.
  37. [37]
    ACVR1 Function in Health and Disease - MDPI
    Activin A receptor type I (ACVR1) encodes for a bone morphogenetic protein type I receptor of the TGFβ receptor superfamily. It is involved in a wide ...Acvr1 Function In Health And... · 2. Fibrodysplasia Ossificans... · 8. Acvr1 In Cancer
  38. [38]
    Activin receptor subunits in normal and dysfunctional adult human ...
    ALK2, ALK4 and ActRIIB proteins were observed in Sertoli cells, spermatogonia and some spermatocytes within normal and gonadotropin-suppressed adult human ...
  39. [39]
    Activin A directly impairs human cardiomyocyte contractile function ...
    Nov 10, 2022 · These findings demonstrate that Activin A acts directly on CMs, which may contribute to the cardiac dysfunction seen in aging populations and in ...
  40. [40]
    Acvr1 (alk2) receptor inhibition to treat neurological diseases
    Regeneration of CNS myelin fails in several neurological diseases, such as multiple sclerosis, neonatal brain injury, and stroke (Franklin and Ffrench-Constant, ...
  41. [41]
    Anti-Mullerian-hormone-dependent regulation of the brain serine ...
    Oct 15, 2008 · BMPR-IA, BMPR-IB and ActR-I (also known as ACVR1 and Alk2) are BMP type-I receptors, whereas TGFβ and activin mediate their signal through TβR-I ...
  42. [42]
    Challenges in the diagnosis of fibrodysplasia ossificans progressiva ...
    Sep 30, 2024 · The ACVR1 gene (Ensembl: ENSG00000115170) is located on chromosome 2 consisting of 9 coding exons [8]. It codes a bone morphogenetic protein ...
  43. [43]
    Molecular consequences of the ACVR1(R206H) mutation ... - PubMed
    Jul 16, 2010 · The R206H mutant showed a decreased binding affinity for FKBP1A/FKBP12, a known safeguard molecule against the leakage of transforming growth ...
  44. [44]
    Variant BMP receptor mutations causing fibrodysplasia ossificans ...
    A small subset of patients with FOP carry variant mutations in ACVR1 altering Gly328 to Trp, Glu or Arg. Since these mutations lie outside the GS domain, the ...
  45. [45]
    Mutational analysis of the ACVR1 gene in Italian patients ... - NIH
    The ACVR1 gene encodes the activin A type I receptor (also known as activin receptor-like kinase 2, ALK2), a receptor for bone morphogenetic proteins (BMPs).
  46. [46]
    Recurrent activating ACVR1 mutations in diffuse intrinsic pontine ...
    ... ACVR1, overlaid with functional protein domains and exon boundaries. In total, 11/52 (21%) of DIPG harboured somatic mutations at four residues, all of ...
  47. [47]
    Loss-of-function of ACVR1 in osteoblasts increases bone mass and ...
    Loss of ACVR1 in osteoblasts increases bone mass and activates Wnt signaling in mice. Wnt inhibitors SOST and DKK1 are both downregulated in the mutant bones. ...Missing: traits | Show results with:traits
  48. [48]
    The ACVR1 gene is significantly associated with growth traits in ...
    The aim of this study was to analyze its phenotypic effects on cattle growth traits. Four variations including two intronic Indels and two exonic SNPs were ...
  49. [49]
    Fibrodysplasia Ossificans Progressiva - GeneReviews - NCBI - NIH
    Jun 11, 2020 · Fibrodysplasia ossificans progressiva (FOP) is characterized by congenital bilateral hallux valgus malformations and early-onset heterotopic ossification.Diagnosis · Clinical Characteristics · Management · Genetic Counseling
  50. [50]
    ACVR1 R206H cooperates with H3.1K27M in promoting diffuse ...
    Mar 4, 2019 · Since the finding of H3.3 and H3.1K27M mutations in DIPG, we and others have discovered that ~25% of DIPG patients harbor activating ACVR1 ...
  51. [51]
    Dominant-negative ALK2 allele associates with congenital heart ...
    Jun 23, 2009 · Serious congenital heart defects occur as a result of improper atrioventricular septum (AVS) development during embryogenesis.Missing: malformations | Show results with:malformations